Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement
- 1 October 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 11 (10) , e006412
Abstract
Background: Transcatheter mitral valve replacement (TMVR) may mature to become a therapeutic option for high-risk patients with severe mitral regurgitation (MR), particularly in patients at high or prohibitive surgical risk. MR patients with preexisting aortic valve prosthesis have been excluded from most TMVR trials because of the potential risks of left ventricular outflow tract obstruction or interaction between the TMVR anchoring mechanism and the aortic prosthesis. We describe the procedural and short-term outcomes of transapical TMVR with the Tiara valve in patients experiencing severe symptomatic MR with previous aortic valve replacement (AVR). Methods and Results: Twelve consecutive high surgical risk patients (11 men; mean age, 75±6 years) with aortic valve prosthesis and severe MR underwent TMVR with Tiara valve. Aortic valves were mechanical in 5 and biological in 7 patients, while 1 patient had previously undergone implantation of a transcatheter valve within a failed bioprosthetic surgical valve. Six patients (50%) had undergone redo surgical aortic valve replacement. Clinical characteristics of the group include prior mitral valve repair in 2, prior coronary bypass grafting surgery in 5, chronic atrial fibrillation in 7, renal failure in 9, and pacemaker/cardiac resynchronization device in 9 patients. Mean Society of Thoracic Surgery score and EuroSCORE II were 10.5±4.4 and 12.4±3.7, respectively. Mean baseline left ventricular ejection fraction was 35.5±5.3% (range, 30%–45%). The Tiara valve was implanted uneventfully in all patients. Device migration or left ventricular outflow tract obstruction was not observed. No patient required conversion to open heart surgery or periprocedural hemodynamic support. Procedural success was 100% with no death, MI, stroke, major bleeding, or access site complications at 30 days. MR was eliminated in all 12 patients immediately after implantation. Conclusions: Transapical mitral valve replacement with the Tiara valve in high-risk patients with severe MR and aortic valve prostheses is technically feasible and can be performed safely.Keywords
This publication has 16 references indexed in Scilit:
- Transcatheter mitral valve replacement: long-term outcomes of first-in-man experience with an apically tethered device– a case series from a single centreEuroIntervention, 2017
- Transcatheter Mitral Valve ReplacementJACC, 2017
- Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular CalcificationJACC: Cardiovascular Interventions, 2016
- Transcatheter Valve-in-Valve and Valve-in-Ring for Treating Aortic and Mitral Surgical Prosthetic DysfunctionJACC, 2015
- Short-Term Results of Transapical Transcatheter Mitral Valve Implantation for Mitral RegurgitationJACC, 2014
- Transcatheter mitral valve implantation with Tiara bioprosthesisEuroIntervention, 2014
- Transapical Mitral Implantation of the Tiara BioprosthesisJACC: Cardiovascular Interventions, 2014
- Tiara: A Novel Catheter-Based Mitral Valve BioprosthesisJACC, 2012
- Left Ventricular Outflow Tract: Intraoperative Measurement and Changes Caused by Mitral Valve SurgeryJournal of the American Society of Echocardiography, 2012
- Obstruction of Left Ventricular Outflow Tract After Mechanical Mitral Valve ReplacementThe Annals of Thoracic Surgery, 2008